Pfizer (PFE) Other Accumulated Expenses (2009 - 2026)

Pfizer (PFE) has 17 years of Other Accumulated Expenses data on file, last reported at $20.1 billion in Q1 2026.

• Quarterly Other Accumulated Expenses changed 0.46% year-over-year to $20.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.1 billion (changed 0.46% YoY) and the FY2025 annual result came in at $19.4 billion, down 1.46% from the prior year.
• Other Accumulated Expenses improved to $20.1 billion in Q1 2026 per PFE's latest filing, from $19.4 billion in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $24.6 billion in Q2 2022 and bottomed at $16.1 billion in Q3 2023.
• The 5-year median for Other Accumulated Expenses is $19.7 billion (2024), against an average of $19.8 billion.
• The widest annual swing landed in 2022, when Other Accumulated Expenses jumped 92.08%; it then slumped 32.49% in 2023.
• Tracing PFE's Other Accumulated Expenses over 5 years: stood at $22.6 billion in 2022, then fell by 9.0% to $20.5 billion in 2023, then declined by 3.98% to $19.7 billion in 2024, then retreated by 1.46% to $19.4 billion in 2025, then climbed by 3.48% to $20.1 billion in 2026.
• Per Business Quant, the three latest PFE Other Accumulated Expenses figures stand at $20.1 billion (Q1 2026), $19.4 billion (Q4 2025), and $19.5 billion (Q3 2025).

Peer Comparison